Akoya Biosciences Stock Analysis

AKYA Stock  USD 1.70  0.02  1.19%   
Akoya Biosciences is undervalued with Real Value of 2.15 and Target Price of 3.5. The main objective of Akoya Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Akoya Biosciences is worth, separate from its market price. There are two main types of Akoya Biosciences' stock analysis: fundamental analysis and technical analysis.
The Akoya Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Akoya Biosciences' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.

Akoya Stock Analysis Notes

About 67.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.12. Akoya Biosciences had not issued any dividends in recent years. Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. Akoya Biosciences operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 319 people. For more info on Akoya Biosciences please contact Brian McKelligon at 855 896 8401 or go to https://www.akoyabio.com.

Akoya Biosciences Quarterly Total Revenue

21.34 Million

Akoya Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Akoya Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Akoya Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Akoya Biosciences generated a negative expected return over the last 90 days
Akoya Biosciences may become a speculative penny stock
Akoya Biosciences has high historical volatility and very poor performance
The company reported the previous year's revenue of 81.67 M. Net Loss for the year was (55.37 M) with profit before overhead, payroll, taxes, and interest of 47.88 M.
Akoya Biosciences currently holds about 87.61 M in cash with (44.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Akoya Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 70.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Akoya Q4 Earnings Snapshot

Akoya Biosciences Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akoya Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Akoya Largest EPS Surprises

Earnings surprises can significantly impact Akoya Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-14
2024-09-30-0.2-0.17860.021410 
2021-08-10
2021-06-30-0.23-0.20.0313 
2024-03-04
2023-12-31-0.27-0.220.0518 
View All Earnings Estimates

Akoya Stock Institutional Investors

Shares
Osterweis Capital Management Inc2024-12-31
126.1 K
Schonfeld Strategic Advisors Llc2024-12-31
122 K
Bridgeway Capital Management, Llc2024-12-31
105.6 K
Ubs Group Ag2024-12-31
85.2 K
Goldman Sachs Group Inc2024-12-31
80.3 K
Charles Schwab Investment Management Inc2024-12-31
63 K
Deutsche Bank Ag2024-12-31
54.8 K
Bank Of New York Mellon Corp2024-12-31
50.7 K
Citigroup Inc2024-12-31
48.8 K
Blue Water Life Science Advisors, Llc2024-12-31
4.7 M
Blackrock Inc2024-12-31
1.6 M
Note, although Akoya Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Akoya Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 84.69 M.

Akoya Profitablity

The company has Profit Margin (PM) of (0.68) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.27.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.60)(0.63)
Return On Capital Employed(0.49)(0.51)
Return On Assets(0.44)(0.47)
Return On Equity(7.29)(6.93)

Management Efficiency

Akoya Biosciences has return on total asset (ROA) of (0.1686) % which means that it has lost $0.1686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8045) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.63. In addition to that, Return On Capital Employed is expected to decline to -0.51. At present, Akoya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 24.5 M, whereas Other Assets are forecasted to decline to 0.86.
Last ReportedProjected for Next Year
Book Value Per Share 0.15  0.15 
Tangible Book Value Per Share(0.51)(0.48)
Enterprise Value Over EBITDA(2.94)(3.09)
Price Book Value Ratio 14.90  15.65 
Enterprise Value Multiple(2.94)(3.09)
Price Fair Value 14.90  15.65 
Enterprise Value109.4 M103.9 M
The strategic vision of Akoya Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Operating Margin
(0.27)
Profit Margin
(0.68)
Beta
1.322
Return On Assets
(0.17)
Return On Equity
(1.80)

Technical Drivers

As of the 23rd of March, Akoya Biosciences shows the Risk Adjusted Performance of (0.06), mean deviation of 3.63, and Standard Deviation of 4.61. Akoya Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Akoya Biosciences Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Akoya Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Akoya Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Akoya Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akoya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Pascal Bamford over a week ago
Disposition of 2567 shares by Pascal Bamford of Akoya Biosciences at 1.63 subject to Rule 16b-3
 
Brian McKelligon over two weeks ago
Disposition of 8257 shares by Brian McKelligon of Akoya Biosciences at 1.63 subject to Rule 16b-3
 
Brian McKelligon over a month ago
Disposition of 226 shares by Brian McKelligon of Akoya Biosciences at 9.918 subject to Rule 16b-3
 
Pascal Bamford over three months ago
Disposition of 25000 shares by Pascal Bamford of Akoya Biosciences at 12.3 subject to Rule 16b-3
 
Mendel Scott over three months ago
Acquisition by Mendel Scott of 44959 shares of Akoya Biosciences at 2.68 subject to Rule 16b-3
 
Niro Ramachandran over six months ago
Acquisition by Niro Ramachandran of 45000 shares of Akoya Biosciences at 12.3 subject to Rule 16b-3
 
Frederic Pla over six months ago
Acquisition by Frederic Pla of 20000 shares of Akoya Biosciences subject to Rule 16b-3
 
Pascal Bamford over six months ago
Disposition of 50000 shares by Pascal Bamford of Akoya Biosciences at 5.35 subject to Rule 16b-3
 
Brian McKelligon over six months ago
Disposition of 7500 shares by Brian McKelligon of Akoya Biosciences at 0.303 subject to Rule 16b-3
 
Brian McKelligon over six months ago
Disposition of 7500 shares by Brian McKelligon of Akoya Biosciences at 2.084 subject to Rule 16b-3
 
Shepler Robert G over six months ago
Acquisition by Shepler Robert G of 120000 shares of Akoya Biosciences at 5.0 subject to Rule 16b-3
 
Brian McKelligon over six months ago
Disposition of 7500 shares by Brian McKelligon of Akoya Biosciences at 2.0085 subject to Rule 16b-3

Akoya Biosciences Outstanding Bonds

Akoya Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Akoya Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Akoya bonds can be classified according to their maturity, which is the date when Akoya Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Akoya Biosciences Predictive Daily Indicators

Akoya Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Akoya Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Akoya Biosciences Forecast Models

Akoya Biosciences' time-series forecasting models are one of many Akoya Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Akoya Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Akoya Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Akoya Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Akoya shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Akoya Biosciences. By using and applying Akoya Stock analysis, traders can create a robust methodology for identifying Akoya entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.68)(0.71)
Operating Profit Margin(0.57)(0.60)
Net Loss(0.68)(0.71)
Gross Profit Margin 0.59  0.65 

Current Akoya Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Akoya analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Akoya analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
3.5Buy8Odds
Akoya Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Akoya analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Akoya stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Akoya Biosciences, talking to its executives and customers, or listening to Akoya conference calls.
Akoya Analyst Advice Details

Akoya Stock Analysis Indicators

Akoya Biosciences stock analysis indicators help investors evaluate how Akoya Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Akoya Biosciences shares will generate the highest return on investment. By understating and applying Akoya Biosciences stock analysis, traders can identify Akoya Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow83.8 M
Long Term Debt76.2 M
Common Stock Shares Outstanding49.4 M
Total Stockholder Equity7.6 M
Tax Provision146 K
Property Plant And Equipment Net13 M
Cash And Short Term Investments35 M
Cash11.8 M
Accounts Payable8.8 M
Net Debt-3.8 M
50 Day M A2.249
Total Current Liabilities29.4 M
Other Operating Expenses128.4 M
Non Current Assets Total48.3 M
Non Currrent Assets Other2.5 M
Stock Based Compensation9.3 M

Complementary Tools for Akoya Stock analysis

When running Akoya Biosciences' price analysis, check to measure Akoya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akoya Biosciences is operating at the current time. Most of Akoya Biosciences' value examination focuses on studying past and present price action to predict the probability of Akoya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akoya Biosciences' price. Additionally, you may evaluate how the addition of Akoya Biosciences to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Global Correlations
Find global opportunities by holding instruments from different markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine